Oral corticosteroids

Preclinical

Sanofi

Oral corticosteroids is one of 3 therapeutic programs targeting Dermatitis, Atopic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dermatitis, AtopicEnrolling by invitation

Dermatitis, AtopicPreclinical

Enrolling by invitation

Competition

Competitive Landscape

3 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

Amlitelimab

Sanofi

Phase 3

7 2

Calcineurin Inhibitors

Sanofi

Preclinical

2 3

Oral corticosteroids

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalActive, not recruiting

Dermatitis, Atopic

NCT05492578

Q1 2031

Phase 3Active, not recruiting

OTC Deficiency

NCT05345171

Clinical

Trials by Indication[1]

Dermatitis, Atopic1 trial

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Active, not recruiting· Sanofi logo

Sanofi·Preclinical·NCT05492578·1,856 enrolled

OTC Deficiency1 trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients With Late-onset OTC Deficiency

Active, not recruiting· Ultragenyx logo

Ultragenyx·Phase 3·NCT05345171·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oral corticosteroids. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Oral corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Sanofi

Oral corticosteroids

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2031

Trials by Indication[1]

Dermatitis, Atopic1 trial

OTC Deficiency1 trial

References

Drug Info

Quick Facts

Related News